

**PE anti-mouse CD278 (ICOS)**

**Catalog # / Size:** 1187030 / 200 µg  
1187025 / 50 µg

**Clone:** 7E.17G9

**Isotype:** Rat IgG2b, κ


**Immunogen:** Mouse ICOS cDNA and ICOS hexahistidine fusion protein

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** 0.2



Con A-stimulated (3 days) C57BL/6 splenocytes stained with 7E.17G9 PE.

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported applications (for the relevant formats) include: blocking of ligand binding. The LEAF™ format is suggested for blocking studies.

**Application References:**

1. Akbari O, *et al.* 2002. *Nat. Med.* 8:1024.
2. Harada H, *et al.* 2003. *J. Clin. Invest.* 112:234.
3. McAdam AJ, *et al.* 2000. *J. Immunol.* 165:5035. (FC Block)
4. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. [PubMed](#)

**Description:** The 7E.17G9 antibody reacts with the 47-57 kD ICOS protein, also known as inducible costimulatory molecule, and H4. This protein is homologous to the CD28/CTLA-4 proteins. ICOS is expressed on activated T cells and a subset of thymocytes and can costimulate T cells and induce proliferation. In addition ICOS has been shown to be involved in humoral immune responses (B cell germinal center formation). The ICOS ligand, B7h/B7RP-1 and B7-H2 is constitutively expressed in B cell areas of secondary lymphoid organs and can be induced in other tissues by LPS. ICOS stimulation has been shown to potentiate TCR-mediated IL-4 and IL-10 production and has been proposed to play a role in Th2 cell development. ICOS stimulation has been shown to be involved in airway tolerance and the downregulation of pulmonary inflammation.

**Antigen References:**

1. Rudd CE, *et al.* 2003. *Nat. Rev. Immunol.* 3:544.
2. McAdam AJ, *et al.* 2000. *J. Immunol.* 165:5035.
3. Mak TW, *et al.* 2003. *Nat. Immunol.* 4:765